CIAO2B

Across TCGA pan-cancer cohorts, CIAO2B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CIAO2B data layer compared with 29 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CIAO2B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CIAO2B expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

PDAC, LSCC, and GBM are the cancer types where CIAO2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	0.342	0.979	.006	16	view →
LSCC	DFS	Median	III,IV	0.621	1.000	.013	6	view →
GBM	OS	Median	All	0.877	0.668	.033	3	view →
HNSC	OS	Median	III,IV	1.000	0.948	.043	3	view →
CCRCC	OS	Median	All	0.780	0.897	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CIAO2B–PDAC (DFS)

Open the PDAC breakdown →